Trial Profile
Efficacy of 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenia syndrome
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2020
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Lambert-Eaton myasthenic syndrome
- Focus Therapeutic Use
- 31 Jul 2018 Status changed from not yet recruiting to discontinued.
- 02 Oct 2017 Planned End Date changed from 31 Mar 2020 to 30 Sep 2020.
- 02 Oct 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.